zurück Home Prognose des Analkarzinoms
Allgemeines 5a-OS Europa: 57% (2)

Differenzierung

5a-Überleben: gut differenziert 75%, schlecht differenziert 25%.

Stadium

Stadium 3a-RFS (1)
I 90%
II 75%
III 61%

Quellen

1.) Roohipour R, et al.:
Squamous cell carcinoma of the anal canal: Predictors of treatment outcome.
Dis Colon Rectum 51(2008):147-153

2.) Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al.:
Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet- a population-based study.
Lancet Oncol 2017;18:1022–39.
doi 10.1016/S1470-2045(17)30445-X.

Impressum                               Zuletzt geändert am 31.12.2022 21:43